Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
None USD 0.00(0%)
Last update at 2025-05-01T13:05:57.195675Z
Market Cap
6927.83M

Momentum Score

…

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
45.50
Low
84.89
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
513.93M
Revenue Per Share
5.34
Gross Profit TTM
95.16M
Debt / Equity
0.03
ROE
-18.07%
Net Debt
-130.83M
ROCE
-43.70%
Diluted EPS TTM
-1.16

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -256.25M -284.12M -226.99M -147.72M -155.13M
Net income -256.26M -284.13M -227.01M -147.72M -155.13M
Selling general administrative 358.78M 272.61M 186.36M 64.95M 30.10M
Gross profit 228.69M 73.67M 20.64M 0.06M -132.17M
Reconciled depreciation 0.66M 0.53M 0.53M 0.48M 0.37M
Ebit -264.28M -286.22M -231.76M -154.49M -162.64M
Ebitda -263.63M -285.69M -231.23M -154.01M -162.27M
Depreciation and amortization 0.66M 0.53M 0.53M 0.48M 0.37M
Non operating income net other 7.38M 1.57M 4.24M 6.29M 7.14M
Operating income -263.63M -285.69M -231.23M -154.01M -162.27M
Other operating expenses 512.76M 367.40M 253.76M 154.07M 162.27M
Interest expense 7.38M 2.10M 4.76M 6.77M 0.00M
Tax provision 0.01M 0.01M 0.01M 0.00M 0.00M
Interest income 7.38M 1.57M 4.24M 6.29M 7.14M
Net interest income 7.38M 1.57M 4.24M 6.29M 7.14M
Income tax expense 0.01M 0.01M 0.01M 0.00M 0.00M
Total revenue 249.13M 81.71M 22.53M 0.06M 0.00M
Total operating expenses 492.31M 359.36M 251.86M 154.07M 162.27M
Cost of revenue 20.44M 8.03M 1.90M 89.12M 132.17M
Total other income expense net 7.38M 1.57M 4.24M 6.29M 7.14M
Net income from continuing ops -256.26M -284.13M -227.01M -147.72M -155.13M
Net income applicable to common shares -256.26M -284.13M -227.01M -147.72M -155.13M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 728.29M 754.78M 489.92M 717.31M 251.19M
Other current assets 42.44M 45.19M 26.84M 15.64M 6.31M
Total liab 136.87M 98.71M 72.03M 60.45M 56.18M
Total stockholder equity 591.42M 656.07M 417.89M 656.86M 195.01M
Other current liab 108.48M 68.27M 37.93M 25.81M 25.61M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -1617.16M -1477.49M -1221.23M -937.10M -710.10M
Other assets - 0.09M 0.09M 0.09M 0.35M
Cash 147.77M 148.62M 92.36M 60.05M 107.64M
Total current liabilities 123.55M 83.24M 53.36M 36.85M 36.22M
Net debt -130.83M -128.57M -66.96M -30.90M -84.49M
Short term debt 3.61M 4.57M 6.73M 5.54M 3.19M
Short long term debt total 16.94M 20.04M 25.41M 29.14M 23.14M
Other stockholder equity 2208.47M 2137.74M 1639.48M 1593.48M 904.97M
Property plant equipment - 1.91M 22.56M 2.00M 2.26M
Total current assets 667.80M 737.96M 467.28M 690.90M 230.32M
Net tangible assets - 656.07M 417.89M 656.86M 195.01M
Short term investments 350.17M 443.29M 319.97M 597.40M 116.37M
Net receivables 114.02M 75.19M 20.16M 10.76M 0.35M
Inventory 11.65M 23.92M 7.95M 7.06M -
Accounts payable 11.45M 10.39M 8.69M 5.50M 7.43M
Accumulated other comprehensive income 0.10M -4.19M -0.36M 0.48M 0.13M
Common stock total equity - 0.01M 0.01M 0.01M 0.01M
Retained earnings total equity - -1477.49M -1221.23M -937.10M -710.10M
Non currrent assets other 45.91M 0.09M 0.09M 0.09M 0.09M
Non current assets total 60.50M 16.82M 22.64M 26.41M 20.86M
Capital lease obligations 16.94M 20.04M 25.41M 29.14M 23.14M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -127.59M 280.67M -480.03M 178.14M 135.03M
Change to liabilities 12.39M 3.19M -1.73M -3.21M 22.17M
Total cashflows from investing activities -128.37M 280.34M -480.30M 177.44M 134.64M
Total cash from financing activities 455.16M 11.52M 664.18M 3.24M 0.69M
Change to operating activities 11.16M 0.74M -7.80M 5.68M 11.63M
Net income -256.26M -284.13M -227.01M -147.72M -155.13M
Change in cash 56.60M 32.32M -46.19M 52.69M 17.16M
Begin period cash flow 93.77M 61.45M 107.64M 54.95M 37.79M
End period cash flow 150.37M 93.76M 61.45M 107.64M 54.95M
Total cash from operating activities -270.19M -259.54M -230.07M -127.98M -118.17M
Issuance of capital stock 433.72M 0.00M 652.71M 0.00M 0.00M
Depreciation 0.66M 0.53M 0.53M 0.48M 0.37M
Other cashflows from investing activities - - - 178.14M 135.03M
Change to inventory -15.97M -0.89M -7.06M -7.06M -7.06M
Change to account receivables -55.03M -9.39M -10.76M -10.76M -10.76M
Sale purchase of stock 455.16M 11.52M 664.18M 3.24M 0.69M
Other cashflows from financing activities 21.44M 11.52M 11.46M 3.24M 0.69M
Change to netincome 43.10M 30.40M 24.59M 21.25M 18.12M
Capital expenditures 0.78M 0.33M 0.27M 0.70M 0.39M
Change receivables -55.03M -9.39M -10.76M - -
Cash flows other operating 0.48M -11.38M -7.99M 2.35M -2.76M
Cash and cash equivalents changes 56.60M 32.32M -46.19M 52.69M 17.16M
Change in working capital -58.14M -6.35M -27.28M -0.59M 19.94M
Stock based compensation 43.01M 34.30M 24.12M 20.79M 17.40M
Other non cash items 0.54M 0.18M 0.21M 0.19M -529.97M
Free cash flow -270.96M -259.87M -230.34M -128.68M -118.56M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MKKGY
Merck KGaA ADR
0.45
1.38%
33.07 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-
-%
170.05 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
0.31
1.47%
21.43 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

Intracellular Th

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

430 East 29th Street, New York, NY, United States, 10016

646 440 9333

610

Name Title Year Born
Dr. Sharon Mates Ph.D. Co-Founder, Chairman, CEO & Pres 1953
Mr. Lawrence J. Hineline CPA, CPA Sr. VP of Fin., CFO, Treasurer & Assistant Sec. 1956
Mr. Michael I. Halstead J.D. Exec. VP, Gen. Counsel & Sec. 1973
Dr. Suresh K. Durgam M.D. Exec. VP & Chief Medical Officer 1969
Mr. Mark Neumann EVP & Chief Commercial Officer 1963
Dr. Robert E. Davis Ph.D. Sr. VP & Chief Scientific Officer 1951
Mr. Juan Fernando Sanchez VP of Corp. Communications & Investor Relations 1971
Ms. Karen Patruno Sheehy Esq. Sr. VP & Chief Compliance Officer 1962
Dr. Michael Olchaskey Sr. VP & Head of Regulatory Affairs NA
Mr. John A. Bardi Sr. VP of Market Access, Policy & Gov. Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…